Germany, Spain and Italy are the initial launch markets for Samsung Bioepis’s Epysqli (eculizumab) biosimilar rival to Soliris in Europe, the company has revealed, detailing the initial steps of its roll-out in response to enquiries from Generics Bulletin.
Samsung Bioepis Outlines European Eculizumab Roll-Out
Epysqli Rival To Soliris Is First Biosimilar Solely Commercialized By Firm In Europe
Samsung Bioepis has offered details on the launch of its Epysqli eculizumab biosimilar rival to Soliris in European markets.
More from Biosimilars
• By
In the wake of a report marking 10 years since the first US biosimilar launch, Cardinal Health’s Dracey Poore speaks to Generics Bulletin about the successes seen so far and the obstacles that must be overcome if the market is to thrive in the decade ahead.
• By
Generics Bulletin reviews global regulatory developments across the world.
• By
Coherus has officially marked its exit from biosimilars by completing the divestment of its Udenyca pegfilgrastim franchise. Meanwhile, buyer Accord BioPharma has set out how it expects to benefit not only from a growing asset but also from the Coherus personnel that have moved over.
• By
After Amgen’s surprise launch of the first US biosimilar to Eylea last year, expectations around competition are being further upended with the news that Biocon Biologics has struck a settlement deal with Regeneron allowing it to launch its own aflibercept rival in the second half of 2026. Will other challengers follow suit?